NovaBay Pharma (NBY) Reports In-Line Q2 EPS

NovaBay Pharma (NYSE: NBY) reported Q2 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $1.01 million versus the consensus estimate of $610 thousand.

For earnings history and earnings-related data on NovaBay Pharma (NBY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M